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 3 
ABSTRACT 1 
 2 
The cell's endogenous antioxidant system is vital to maintenance of redox homeostasis. Despite its 3 
central role in normal and pathophysiology, no non-invasive tools exist to measure this system in 4 
patients. The cystine/glutamate antiporter system xc- maintains the balance between intracellular 5 
reactive oxygen species and antioxidant production through the provision of cystine, a key 6 
precursor in glutathione biosynthesis. Here we show that tumor cell retention of a system xc--7 
specific positron emission tomography radiotracer, (S)-4-(3-[18F]fluoropropyl)-L-glutamic acid 8 
([18F]FSPG), decreases in proportion to levels of oxidative stress following treatment with a range 9 
of redox-active compounds. The decrease in [18F]FSPG retention correlated with a depletion of 10 
intracellular cystine resulting from increased de novo glutathione biosynthesis, shown through [U-11 
13C6, U-15N2]cystine isotopic tracing. In vivo, treatment with the chemotherapeutic doxorubicin 12 
decreased [18F]FSPG tumor uptake in a mouse model of ovarian cancer, coinciding with markers 13 
of oxidative stress but preceding tumor shrinkage and decreased glucose utilization. Having 14 
already been used in pilot clinical trials, [18F]FSPG PET could be rapidly translated to the clinic 15 
as an early redox indicator of tumor response to treatment.  16 
 4 
INTRODUCTION 1 
 2 
Mammalian cells have developed an exquisite system of biochemical processes with which to 3 
maintain redox homeostasis. The overall purpose of this system is to prevent damage from 4 
unregulated redox reactions. For example, harmful reactive oxygen species (ROS) generated 5 
during oxidative phosphorylation are buffered by the activity of multiple enzymes including 6 
superoxide dismutase, catalase, and glutathione peroxidase, which convert ROS to increasingly 7 
benign products. Other toxic redox-active compounds include exogenous electrophiles, which can 8 
be neutralized by an array of intracellular antioxidants, such as glutathione (GSH) and thioredoxin 9 
(Trx), along with associated oxidoreductase enzymes. While these mechanisms are usually 10 
sufficient to maintain redox homeostasis, prolonged or elevated exposure to ROS or exogenous 11 
electrophiles can result in damage to DNA, proteins and cell membranes (reviewed in (1)). The 12 
consequences of redox dysregulation – cumulatively referred to as oxidative stress – play an 13 
important role in a myriad of diseases, including cancer (2, 3), arthritis (4), cardiovascular disease 14 
(5), Alzheimer’s disease and Parkinson’s disease (6). 15 
 16 
Cancer cells reprogram their metabolism to meet the energetic and biosynthetic demands 17 
accompanying elevated rates of replication (7). A common consequence of this metabolic 18 
adaptation is an elevation in ROS (8). To avoid the cytotoxicity associated with high ROS levels, 19 
cancer cells can adapt by upregulating key antioxidant molecules such as GSH and Trx (9). 20 
Additionally, many chemotherapeutic agents are known to produce oxidative stress, as evidenced 21 
by elevation of lipid peroxidation products, diminished radical-trapping capacity of blood plasma, 22 
decreased plasma levels of antioxidants such as vitamin E, vitamin C, and β-carotene, and the 23 
 5 
marked depletion of tissue GSH (10-12). Not surprisingly, acquired resistance to 1 
chemotherapeutics is often associated with increased levels of antioxidants (e.g. GSH, Trx) and 2 
associated oxidoreductases (e.g. GSH peroxidase and γ-glutamyl transpeptidase) (9, 13).  3 
 4 
Given the importance of redox processes in cancer, a sensitive and non-invasive measure of 5 
cellular redox status would enable a greater understanding of mechanisms that drive disease 6 
progression, chemotherapy response and resistance. A number of in vivo redox imaging 7 
approaches are currently under preclinical development, including ROS-sensitive PET radiotracers 8 
(14-16), the cystine analog [18F]FASu (17, 18), redox-sensitive MRI contrast agents (19), and 9 
hyperpolarized magnetic resonance spectroscopy imaging (MRSI) techniques (20, 21). The 10 
validation of these techniques, however, are at a relatively preliminary stage and none have been 11 
translated to human use. The lack of translational redox imaging techniques represents a major gap 12 
in the arsenal of human imaging methods. Here, we use the PET radiotracer (S)-4-(3-13 
[18F]fluoropropyl)-L-glutamic acid ([18F]FSPG) as an in vivo probe of intracellular redox status. In 14 
patients, [18F]FSPG PET has been used to image a range of malignancies, including lung, liver and 15 
brain cancers (22-25). However, the link between [18F]FSPG uptake and tumor redox status has 16 
not been previously investigated. 17 
 18 
[18F]FSPG enters the cell via the system xc- membrane transporter (26), a heterodimeric transporter 19 
comprising the functional transporter, xCT/SLC7A11, and SLC3A2, a membrane protein common 20 
to several amino acid transporters. Physiologically, system xc- functions as a cystine/glutamate 21 
antiporter, allowing extracellular cystine, the dimeric form of cysteine, to be taken up in exchange 22 
for intracellular glutamate (27). Within the cell, cystine is reduced to cysteine (28), the rate-23 
 6 
limiting substrate in the biosynthesis of GSH (29), the cell’s most abundant small molecule 1 
antioxidant (30). System xc--derived cystine represents one of the primary sources of intracellular 2 
cysteine, particularly under conditions of oxidative stress when system xc- expression and cysteine 3 
demand are increased (31). High levels of system xc- expression result in increased cystine influx 4 
(32) and GSH biosynthesis (33), processes which utilize intracellular glutamate as an exchange 5 
partner and biosynthetic precursor, respectively. This xc-/cystine-mediated shunting of glutamate 6 
away from anaplerotic reactions is thought to be the driving force behind reduced glutamine 7 
dependence observed in tumors when compared to cells grown in culture (32).   8 
 9 
Specific uptake via system xc- transport places [18F]FSPG at a central position within the cell’s 10 
antioxidant system. Accordingly, we hypothesized that [18F]FSPG PET would provide a useful 11 
tool for in vivo imaging of cellular redox status. Moreover, the fact that [18F]FSPG has already 12 
been used in pilot clinical trials provides the possibility for its rapid translation to human redox 13 
imaging.  In this study we characterize changes in [18F]FSPG retention in response to oxidant and 14 
antioxidant treatments. Using a metabolomics approach, we then address the molecular 15 
mechanisms underlying the observed changes in [18F]FSPG uptake. Finally, we evaluate the utility 16 
of [18F]FSPG for in vivo imaging of tumor redox status in a mouse model of ovarian cancer, and 17 
assess its potential for the detection of redox changes that occur during chemotherapy.  18 
 7 
MATERIALS AND METHODS 1 
 2 
Cell lines 3 
Human ovarian cancer A2780 cells were obtained from Sigma-Aldrich, PEO1 and PEO14 cells 4 
from Public Health England Culture Collections, and SKOV3 cells were donated by Dr. Anil K. 5 
Sood (MD Anderson Cancer Centre, USA). A2780 and SKOV3 cells were selected as well-6 
characterized cell models of human ovarian cancer, with patient-derived PEO1 and PEO14 cells 7 
taken from two patients with high grade serous ovarian cancer that were classified as 8 
chemotherapy-sensitive. A2780 and SKOV3 cells were cultured in RPMI media supplemented 9 
with 10% FBS. PEO1 and PEO14 cells were cultured in RMPI media supplemented with 10% 10 
FBS and 2 mM sodium pyruvate. All cell lines were maintained at 37 °C and 5% CO2 in a 11 
humidified atmosphere, with mycoplasma testing performed on a monthly basis. Cells were 12 
authenticated by short tandem repeat profiling just prior to submission and kept within 10-15 13 
passages of the original frozen vial. 14 
 15 
Animal subjects 16 
Female immunodeficient nu/nu BALB/c mice (8-10 weeks) were used and were obtained from 17 
either Charles River Laboratories (UK) or Envigo (UK). Assignment of mice to treatment groups 18 
were done randomly. All animal experiments performed at University College London were done 19 
in accordance with UK government Animals (Scientific Procedures) Act and according to 20 
institutional regulations, with experimental procedures involving animals performed at Stanford 21 
University approved by the Stanford University Institutional Animal Care and Use Committee. 22 
 23 
 24 
 8 
 1 
Cell drug treatments 2 
Except where specifically noted, cells were seeded 24 h prior to treatment at a density of 5.3  104 3 
cells/cm2 (corresponding to 5  105 cells per well on a 6-well plate). For 24 h treatments, seeding 4 
densities were: A2780, 5.3  104 cells/cm2; PEO1, 2.6  104 cells/cm2; PEO14, 1.3  104 cells/cm2. 5 
Fresh media was provided at least 1 h prior to drug treatments, and for treatment durations 24 h 6 
for longer, fresh media including drug was given 1 h prior to any experimental determinations. 7 
TBHP was administered 1 h prior to assay at a final concentration of 200 µM. NAC was added 1h 8 
prior to TBHP administration (2 h total treatment duration) at a final concentration of 5 mM. Cells 9 
were treated with butein (BUT) and diethyl maleate (DEM) 24 h prior to assay, whereas Doxil 10 
(DOX) was administered 72 h prior to assay. All remaining drugs were added 1 h prior to assay. 11 
Final concentrations were: BUT, 100 µM; rotenone (ROT), 50 µM; auranofin (AUR), 50 µM; 12 
antimycin A (AMA), 1.10 µg/mL; DEM, 100 µM; DOX, 200 nM. 13 
 14 
Flow cytometric measurement of intracellular reactive oxygen species (ROS) and cell death 15 
Following drug treatment, CellROX Orange or CellROX Green (Invitrogen) was added to each 16 
well at a final concentration of 5 µM according to the manufacturer’s instructions. For cell death 17 
experiments cells were resuspended in 200 µL of HBSS, with Annexin V-Alexa Fluor 488 (5 µL 18 
stock/100 µL cell suspension) and Sytox Red (5 nM final concentration) added and samples 19 
incubated for 15 min in the dark. Samples were analyzed on a BD LSR Fortessa X-20 flow 20 
cytometer. A total of 20,000 single cell events were recorded. Data were gated post-acquisition to 21 
include only single cells, and the corresponding fluorescence histograms and median fluorescence 22 
intensities (MFI) were extracted using FlowJo software (v. 10.1). 23 
 9 
 1 
Measurement of intracellular GSH 2 
Cells were seeded at a density of 4  104 cells per well in 96-well plates. Following drug treatment, 3 
medium was aspirated and the cells were rapidly washed on ice with ice-cold PBS (3  200 µL). 4 
GSH measurements were then carried out directly on the plate using the GSH/GSSG-Glo Assay 5 
kit (Promega, UK) according to manufacturer’s instructions. Estimates of reduced GSH were 6 
obtained as the difference between total and oxidised GSH. Data were expressed as the ratio of 7 
GSSG:GSH.  8 
 9 
Measurement of intracellular glutamate 10 
To examine the relationship between intracellular glutamate and [18F]FSPG retention, cells were 11 
incubated for various durations in glutamine/FBS-free media. After all treatments, the medium 12 
was aspirated and the cells were washed with 1 mL of warmed Dulbecco’s phosphate buffered 13 
saline (DPBS). The cells were trypsinized and washed three times by centrifugation (600  g, 4 °C 14 
for 3 min) and resuspension in ice-cold PBS. The final cell pellet was resuspended in 200 µL of 15 
ice-cold glutamate assay buffer (Biovision). The cells were then placed on ice and lysed by 16 
sonication using a Hielscher UP50H ultrasonic processor for three sets of six 0.5 s pulses. The 17 
lysed sample was then centrifuged at 15,000  g, 4 °C for 10 min, and the supernatant analyzed 18 
using the Biovision Glutamate Colorimetric Assay according to manufacturer’s instructions. 19 
Protein content was determined using the Pierce BCA Protein Assay Kit (Thermo Fisher) and the 20 
glutamate content was expressed as nmol/mg protein. 21 
 22 
Metabolomics measurements 23 
 10 
For detailed metabolomics protocol please see Supplemental Materials and Methods. 1 
 2 
Western blotting 3 
Western blot analysis was accomplished using previous described methodology (34), adapted for 4 
use with the iBind Flex system for primary and secondary antibody immunoblotting, according to 5 
the manufacturer’s instructions. Monoclonal antibodies to rabbit anti-human system xc-, GLS, 6 
KGA, NRF2, p53, GCL, caspase-3 and cleaved-caspase-3 (1:1000 dilution) were used for western 7 
blot analysis of both A2780 cell lysates and tumor lysates. Actin was used as a loading control for 8 
all experiments (1:1000 dilution). 9 
 10 
In vivo tumor model 11 
Immunocompromised Balb/c nude mice received a subcutaneous injection of 5 ×106 A2780 cells 12 
in 100 µL PBS at a location approximately between the scapulae on the dorsal surface. Daily 13 
caliper measurements were made on the growing tumors. The volume was estimated by the 14 
formula: (length × width × depth × π)/6. When any individual tumor reached 100 mm3 in volume 15 
(day 0), the animal was assigned to one of three groups: untreated, 24 h Doxil treatment, or 6 day 16 
Doxil treatment. Untreated animals received no treatment, animals in the 24 h Doxil group 17 
received a single intraperitoneal injection of 10 mg/kg Doxil on day 0, and the animals in the 6 d 18 
Doxil group received Doxil on days 0, 2 and 5. PET experiments with either [18F]FSPG or 19 
[18F]FDG were performed on days 0, 1 and 6 in the untreated, 24 h, and 6 d Doxil treatment groups, 20 
respectively. In the [18F]FSPG experiment, each animal was scanned at days 0, 1 and 6, whereas 21 
in the [18F]FDG experiment a separate group of animals was scanned on each of the three days. 22 
Immediately following [18F]FDG scanning, the tumors were excised, divided into four 23 
 11 
approximately equal sized pieces, weighed, rapidly frozen in liquid nitrogen and stored at -80 °C 1 
for ex vivo analysis. 2 
 3 
Ex vivo analysis of tumor tissue samples 4 
Impact-resistant tubes containing Lysing Matrix D (MP Biomedicals) were pre-loaded with 300 5 
µL GSH buffer (Promega), with or without 1 mM N-ethyl maleimide (NEM) for determination of 6 
GSSG or total GSH, respectively. Separate tubes were pre-loaded with 500 µL of RIPA buffer 7 
containing Halt protease and phosphatase inhibitor cocktail (ThermoFisher Scientific) for 8 
preparation of samples for Western blot analysis. Into these tubes were placed the tissue samples 9 
and the tissue was lysed by rapid shaking for 15 s at 4 °C using a FastPrep-24 homogenizer (MP 10 
Biomedicals). The resulting lysates were centrifuged at 15,000  g, 4 °C for 10 min to pellet 11 
insoluble debris. The supernatant was analyzed for total glutamate, GSH (oxidized and reduced), 12 
and the expression of specific proteins, as described above. Metabolite levels were normalized to 13 
sample protein content as described above.  14 
 15 
Radiotracer synthesis 16 
The radiotracer [18F]FSPG was prepared using an automated HotBox III module (Scintomics, 17 
Fürstenfeldbruck, Germany) (35). The protocol has been adapted from a previously reported 18 
method (26). For full details see Supplemental Materials and Methods. [18F]FSPG was obtained 19 
with a decay-corrected radiochemical yield of 42 ± 7% (radiochemical purity >99 %, n = 22) after 20 
110-120 min. A final radioactive concentration of up to 221 MBq/mL of formulated tracer was 21 
achieved. The specific radioactivity was in the range of 4.2-21.9 GBq/µmol. 22 
 23 
 12 
Radiotracer cell uptake experiments 1 
Cells were seeded at the appropriate density in 6-well plates (see above). Drug treatments, in 2 
triplicate, were carried out as described above, after which 185 kBq of either [18F]FSPG or 3 
[18F]FDG was added. After a 60 min uptake period at 37 °C cells were processed according to 4 
previously-described methodology (36). Radioactivity in samples was expressed as a percentage 5 
of the administered dose per mg protein.  6 
 7 
Positron emission tomography experiments 8 
Mice were anaesthetized with isoflurane (2.5% in oxygen) and maintained at 37 °C using an air-9 
heated scanning bed. A cannula was inserted in the tail vein and a 3.7 MBq bolus of either 10 
[18F]FSPG or [18F]FDG was administered in approximately 100 µL of PBS. Mice were then 11 
allowed to recover from anaesthesia, and forty minutes later a 20 min PET acquisition was 12 
performed on a Mediso nanoScan PET/CT system under isoflurane anaesthesia (1.5-2%). 13 
Attenuation correction was done using CT data (50 kVp, 480 projections) and static reconstruction 14 
was done using the Tera-Tomo 3D reconstruction algorithm, with 4 iterations, 6 subsets, a binning 15 
window of 400-600 keV, and a voxel size of 0.4 mm. The resulting reconstructed images were 16 
analyzed using VivoQuant software (v. 2.5, Invicro Ltd.). Tumor volumes of interest were 17 
compiled from sequential 2D regions of interest drawn on the CT images. The radioactivity 18 
concentration in each volume of interest was expressed as a percentage of the injected dose per 19 
mL of tissue volume (%ID/mL). 20 
 21 
 22 
 23 
 13 
Quantification and statistical analysis 1 
Statistical tests and linear regression analyses were performed using GraphPad Prism software (v. 2 
10.1). Comparisons were considered statistically significant went p < 0.05. In all analyses, 3 
Bonferroni multiple comparison corrections were applied when appropriate. For normalized flow 4 
cytometric data, fold change in median fluorescence intensity was assessed using single sample 5 
two-tailed t tests (versus unity). For correlation plots the measure of goodness-of-fit (R2) was 6 
determined, with an F test used to assess whether the line of regression was significantly different 7 
from zero. For all other data, standard two-tailed t tests were used.  8 
 14 
RESULTS 1 
 2 
[18F]FSPG accumulation in tumor cells is altered following manipulation of the intracellular 3 
redox environment 4 
In order to evaluate [18F]FSPG accumulation as a surrogate marker of intracellular redox status, 5 
A2780 ovarian cancer cells were treated with the oxidant tert-butyl hydroperoxide (TBHP), alone 6 
or following pre-treatment with the antioxidant N-acetylcysteine (NAC), and compared with 7 
untreated cells. In response to TBHP alone, cells displayed several hallmark features of oxidative 8 
stress: levels of ROS, as measured by the fluorophore CellROX Orange, were elevated 5.6-fold (p 9 
< 0.0001; Fig. 1A), and the ratio of oxidized (GSSG) to reduced GSH was doubled (Fig. 1B). In 10 
addition, protein expression of the antioxidant transcription factor Nrf2 and the cell cycle regulator 11 
p53 were increased upon TBHP treatment (Fig. 1C), indicating transcriptional up-regulation of 12 
cellular antioxidant defenses, DNA damage and potential cell cycle arrest. TBHP, however, did 13 
not induce cell death at this dose, as shown by an absence of cleaved caspase-3 and by flow 14 
cytometric measurements using annexin V and Sytox Red (Fig. 1D). In contrast, NAC treatment 15 
alone did not alter ROS levels (Fig. 1A) or the ratio of GSSG to GSH (Fig. 1B), suggesting low 16 
levels of oxidative stress under baseline cell culture conditions. Following NAC pre-treatment, 17 
however, TBHP-mediated oxidative stress was greatly diminished, with the levels of ROS and the 18 
ratio of GSSG to GSH similar to untreated cells (Fig. 1A and B).  19 
 20 
We next examined the accumulation of [18F]FSPG under TBHP/NAC treatment conditions (Fig. 21 
1E). Following TBHP-induced oxidative stress, [18F]FSPG cell-associated radioactivity was 22 
decreased from 11.0 ± 0.6 % radioactivity/mg protein in untreated cells, to 5.9 ± 1.6 % 23 
 15 
radioactivity/mg protein following TBHP treatment (p < 0.001; Fig. 1F). Decreased [18F]FSPG 1 
accumulation was also seen in PEO1, PEO14 and SKOV3 ovarian cancer cells upon TBHP 2 
treatment, where it was also associated with increased ROS, demonstrating that [18F]FSPG’s 3 
sensitivity to redox status was not cell line-specific (Supplementary Fig. S1). In A2780 cells, 4 
treatment with NAC resulted in a doubling of [18F]FSPG cell-associated radioactivity when 5 
administered alone (11.0 ± 0.6 % radioactivity/mg protein in untreated cells and 22.6 ± 3.5 % 6 
radioactivity/mg protein following NAC treatment; p < 0.0001). When given as a pretreatment, 7 
NAC prevented the decrease in [18F]FSPG accumulation seen with TBHP administration (Fig. 8 
1F). By comparison, [18F]2-fluoro-2-deoxy-D-glucose ([18F]FDG) uptake, a marker of glucose 9 
utilization, was decreased by TBHP, but this effect was not prevented by NAC pre-treatment, nor 10 
was there any effect seen following NAC treatment alone (Fig. 1G). 11 
 12 
Decreased [18F]FSPG accumulation is correlated with the degree of oxidative stress 13 
In order to investigate whether changes in [18F]FSPG accumulation robustly reflected drug-14 
induced oxidative stress, we identified a panel of mechanistically-diverse redox-active compounds 15 
and measured their impact on ROS and corresponding changes in [18F]FSPG uptake (Fig. 2). The 16 
compounds selected were diethyl maleate, an electrophile which causes GSH depletion; antimycin 17 
A, an electron transport chain complex III inhibitor; rotenone, an electron transport chain complex 18 
I inhibitor; auranofin, a thioredoxin reductase 1 inhibitor; and butein, an inhibitor of signal 19 
transducer and activator of transcription 3 (STAT3). In A2780 cells, the magnitude of treatment-20 
induced ROS varied considerably between these compounds, ranging from a 50 % to 330 % 21 
increase (Fig. 2A). The changes in ROS were paralleled by decreases in [18F]FSPG accumulation, 22 
ranging from 15 % to 78 %  relative to vehicle-treated control cells (Fig. 2B). Importantly, there 23 
 16 
was a strong correlation between ROS induction and [18F]FSPG retention (r = -0.92, R2 = 0.85, p 1 
= 0.009; Fig. 2C).  2 
 3 
Redox-related changes in [18F]FSPG accumulation are associated with alterations in the 4 
concentration of intracellular cystine 5 
Having determined that drug-induced oxidative stress paralleled changes in [18F]FSPG  6 
accumulation, we next investigated the molecular mechanisms that linked these two outcomes. 7 
Levels of xCT protein, the transporter component of heterodimeric system xc-, were unchanged by 8 
either oxidizing or antioxidant treatments (Fig. 1C), ruling out changes in transporter protein 9 
expression as an explanation for the observed differences in [18F]FSPG uptake. The extracellular 10 
concentrations of the system xc- substrates, cystine and glutamate, have previously been shown to 11 
affect [18F]FSPG cell uptake (26). Furthermore, both glutamate and cystine are substrates for GSH 12 
biosynthesis. We therefore hypothesized that increased GSH biosynthesis under oxidative stress 13 
would diminish intracellular pools of cystine and/or glutamate and thereby affect levels of 14 
[18F]FSPG retention. A schematic representation of the putative factors influencing [18F]FSPG cell 15 
retention is shown in Fig. 3A. 16 
 17 
The sensitivity of [18F]FSPG retention to levels of intracellular glutamate was tested by incubating 18 
cells in glutamine-free media. Removal of glutamine resulted in a rapid depletion of intracellular 19 
glutamate, from 107 ± 21 nmol/mg protein to 46 ± 16 nmol/mg protein after 2h glutamine 20 
withdrawal (p < 0.0001, n = 3; Supplementary Fig. S2). This glutamate depletion resulted in a 21 
concomitant decrease in [18F]FSPG cell-associated radioactivity, from 8.17 ± 0.56 % 22 
radioactivity/mg protein to 3.72 ± 0.51 % radioactivity/mg protein (p < 0.0001, n = 3). Both 23 
 17 
[18F]FSPG retention and intracellular glutamate levels were further decreased over the 6 hour time 1 
course of glutamine depletion, with [18F]FSPG accumulation strongly correlated to the 2 
intracellular concentration of glutamate (R2 = 0.80, p < 0.0001; Supplementary Fig. S2). Redox 3 
manipulation with TBHP, NAC or the combined treatment, however, had no effect on intracellular 4 
or extracellular glutamate in A2780 cells (Fig. 3B and C; p > 0.05, n = 3-4), nor were there changes 5 
in expression of glutaminase enzymes which serve as a major source of cellular glutamate through 6 
glutaminolysis (Fig. 1C). In contrast, intracellular cystine concentrations mirrored the pattern of 7 
[18F]FSPG accumulation (Fig. 3D), with lowered cystine measured in lysates from TBHP-treated 8 
cells, increased cystine present following NAC treatment, and intermediate levels seen after the 9 
combined treatment. NAC treatment also dramatically decreased extracellular cystine levels (Fig. 10 
3E), whereas TBHP had no such effect. In addition, [18F]FSPG cell retention was markedly 11 
dependent on the concentration of extracellular cystine (Supplementary Fig. S2).  12 
 13 
Oxidative stress decreases intracellular cystine via stimulation of GSH biosynthesis. 14 
We next used isotopic tracing to identify the mechanism underlying the changes in cystine that 15 
follow oxidative stress. We incubated A2780 cells in cystine-free media supplemented with [U-16 
13C6, U-15N2]cystine to isotopically follow the fate of cystine through key metabolites in the GSH 17 
biosynthetic pathway, shown in Fig. 4A. TBHP treatment resulted in a large and progressive 18 
decrease in intracellular [U-13C6, U-15N2]cystine (Fig. 4B), confirming our previous steady-state 19 
measurements. Heavy isotope-labeled cysteine was also reduced upon TBHP treatment (Fig. 4C), 20 
however, a small increase in isotopic enrichment was seen for γ-glutamylcysteine (Fig. 4D) and 21 
reduced GSH (Fig. 4E) under these oxidizing conditions. Looking to the furthest point downstream 22 
(Fig. 4F), TBHP treatment resulted in increased isotopic enrichment of both single (M+4) and dual 23 
 18 
(M+8) labeled GSSG, indicating that increased flux into GSH biosynthesis is at least partly 1 
responsible for the decrease in intracellular cystine. Incorporation of two heavy-labeled cystines 2 
into GSSG occurred at a slower rate than single label incorporation given the large preexisting 3 
pool of unlabeled GSH, with elevated flux of cystine into M+8 GSSG following TBHP treatment 4 
evident by 60 min (Supplementary Fig. S3). NAC-induced cystine changes were also investigated 5 
using a steady-state approach with unlabeled cystine. Here, we found that the decrease in 6 
extracellular cystine upon NAC treatment (Fig. 2D) was the result of a disulfide exchange reaction 7 
in which cystine is largely replaced by a NAC-cysteine disulfide species (Supplementary Fig. 8 
S4). This disulfide exchange reaction also occurred intracellularly, as evidenced by the appearance 9 
of the NAC-cysteine conjugate.  10 
 11 
[18F]FSPG PET detects changes in tumor redox status prior to tumor shrinkage or decreased 12 
[18F]FDG uptake.  13 
We next examined the effect of the commonly-used chemotherapeutic doxorubicin on in vivo 14 
[18F]FSPG tumor retention as a surrogate marker of therapy response. Using the liposomal form 15 
of the drug (Doxil), we first confirmed the effect of doxorubicin on [18F]FSPG accumulation and 16 
intracellular markers of oxidative stress in A2780 ovarian cancer cells grown in culture. As shown 17 
in Supplementary Fig. S5, 72h Doxil treatment resulted in a large decrease in [18F]FSPG cell-18 
associated radioactivity from 10.8 ± 1.6 to 2.5 ± 0.1 % radioactivity/mg protein (p < 0.001) which 19 
was associated with increased ROS, a decrease in total GSH, and an increase in the ratio of GSSG 20 
to GSH. 21 
 22 
 19 
In A2780 ovarian tumor-bearing mice, [18F]FSPG PET was characterized by high uptake in the 1 
tumor and pancreas, tissues with elevated system xc--expression. The remaining activity was 2 
cleared via the urinary tract to produce excellent tumor-to-background contrast (Supplementary 3 
Fig. S6). A2780 tumor-bearing mice were subsequently treated with Doxil over a six day treatment 4 
time course (Fig. 5A), with tumor response to therapy imaged by [18F]FSPG PET. Tumor growth 5 
rate was unaffected by a single bolus of Doxil (Fig. 5B), however a second round of treatment 6 
resulted in a reduction in tumor volume between days 3 and 6, yielding tumors on day 6 that were 7 
similar in volume to their original size prior to therapy. In tumors, total GSH dropped from 19.1 ± 8 
2.3 nmol/mg protein to 12.6 ± 3.0 nmol/mg protein (p < 0.05) just 24 h post-Doxil treatment (Fig. 9 
5C), indicating changes in tumor redox status that precede, by two days, a reduction in tumor 10 
volume indicative of chemotherapy response. Further changes in tumor redox status were seen in 11 
the ratio of GSSG to GSH, which increased over the course of treatment from 0.010 ± 0.005 to 12 
0.27 ± 0.18 after 6 days treatment (p < 0.01; Fig. 5D). Doxil treatment increased levels of p53, and 13 
to a lesser extent cleaved caspase-3, providing further evidence of a positive response to therapy 14 
(Supplementary Fig. S6). Surprisingly, no increase in levels of the antioxidant transcription factor 15 
Nrf2 or the GSH biosynthetic enzyme glutamate-cysteine ligase (GCL) were observed. There were 16 
also no changes in tumor xCT protein levels with Doxil treatment (Supplementary Fig. S6). 17 
 18 
In tumors, [18F]FSPG retention decreased by 42% just 24 h after Doxil treatment, from 4.35 ± 0.87 19 
% ID/mL in untreated animals (Movie S1), to 2.25 ± 0.91 % ID/mL (p < 0.01; Fig. 5E, F and 20 
Movie S2). This decrease in tumor-associated [18F]FSPG coincided with Doxil-induced depletion 21 
of GSH (Fig. 5C), but occurred prior to any observable tumor shrinkage, (Fig. 5B). Decreased 22 
[18F]FSPG tumor retention was still evident 6 days after treatment (2.28 ± 1.23 %ID/g, p < 0.01 23 
 20 
relative to untreated mice; Movie S3). Representative sagittal and axial images are shown in 1 
Supplementary Fig. S6. By comparison, [18F]FDG uptake was unchanged after 24 h of treatment, 2 
when tumor redox changes became apparent, but was significantly decreased at the 6 day time 3 
point, from 4.85 ± 1.29 % ID/mL on D0 to 2.28 ± 1.23 % ID/mL on D6, when tumor shrinkage 4 
was evident (p < 0.05; Supplementary Fig. S6).  5 
 21 
DISCUSSION 1 
 2 
Despite the clinical importance of tumor antioxidant responses, development of non-invasive tools 3 
for the assessment of this highly-regulated system remains a major unmet clinical need. Here, we 4 
have shown that the PET radiotracer [18F]FSPG, already used in pilot clinical trials, can be used 5 
to monitor spatiotemporal changes in redox status. A key finding of this study is that [18F]FSPG 6 
tumor retention provides an index of redox status through its sensitivity to levels of intracellular 7 
cystine. System xc--derived cystine plays a central role in redox biochemistry. Indeed, 8 
pharmacological inhibition of system xc- results in greatly reduced cellular GSH (37) and system 9 
xc- knock out mice show decreased levels of GSH in the blood (38). Intracellularly, system xc--10 
derived cystine is rapidly reduced to cysteine, which itself plays a crucial role in antioxidant 11 
processes. In addition to its role in GSH biosynthesis, cysteine can act as an antioxidant, protecting 12 
the cell during conditions of GSH depletion (39). Transmembrane cycling of the cystine-cysteine 13 
redox pair is also important in maintenance of both intra- and extracellular redox homeostasis (40). 14 
Cystine levels therefore represent a point of convergence between multiple arms of the cell’s 15 
antioxidant system, making the responsiveness of [18F]FSPG uptake to this amino acid a valuable 16 
surrogate marker of oxidative stress. 17 
 18 
The changes that we observe in [18F]FSPG retention with oxidative stress can be understood by 19 
considering the mechanism of system xc- transport. The cystine/glutamate exchange activity of 20 
system xc- is mediated by the membrane concentration gradients of the exchanged species, 21 
glutamate (high intracellular, low extracellular) and cystine (low intracellular, high extracellular) 22 
(27). Consequently, both amino acids are exchanged along their concentration gradients, with 23 
 22 
glutamate leaving and cystine entering the cell. [18F]FSPG acts as a third exchange partner in this 1 
exchange system, and as expected, its cell retention was influenced by levels of cystine or 2 
glutamate. Additionally, both cystine and glutamate can act competitively (41), preventing 3 
interaction of [18F]FSPG with system xc- (26). Thus, there are two potential mechanisms by which 4 
changes in levels of cystine or glutamate could affect [18F]FSPG retention: through changes in the 5 
amino acid gradients across the plasma membrane, or through altered levels of competition at the 6 
site of the transporter. A schematic depicting these processes is shown in Fig. 3A. Kinetic analysis 7 
of dynamic imaging data may help further elucidate the mechanism of [18F]FSPG trapping and 8 
retention, taking into account both cellular transport and blood flow. Our findings confirm the 9 
sensitivity of [18F]FSPG retention to changes in levels of either amino acid (Fig. 3 and 10 
Supplementary Fig. S2). However, during oxidative stress glutamate levels remain unchanged, 11 
implicating the observed depletion of intracellular cystine as the factor mediating changes in 12 
[18F]FSPG uptake.  13 
 14 
Using a metabolomics approach, we explored the connection between oxidative stress and changes 15 
in cystine metabolism. We found that the decrease in intracellular cystine following TBHP 16 
treatment was the result of an increase in flux of cystine through the GSH biosynthetic pathway. 17 
Using heavy isotope-labeled cystine, TBHP produced a selective isotopic enrichment of GSSG, 18 
indicating increased GSH biosynthesis and subsequent oxidation. This finding provides a direct 19 
mechanistic connection between oxidative stress, intracellular cystine levels and [18F]FSPG 20 
uptake. Isotopic enrichment of reduced GSH was only marginally increased in stressed over 21 
untreated cells, probably reflecting both the far larger GSH pool compared to GSSG (100) and 22 
the relatively short enrichment time of 60 min. Whereas oxidative stress changed only intracellular 23 
 23 
cystine levels, the antioxidant NAC altered both intracellular and extracellular concentrations of 1 
cystine. The extracellular changes were accounted for by a disulfide exchange reaction between 2 
NAC and cystine, which converted virtually all extracellular cystine to free cysteine and a NAC-3 
cysteine mixed disulfide species. NAC also resulted in an increase in intracellular cystine, 4 
potentially by providing cysteine through deacetylation of NAC (42). 5 
 6 
Unlike other redox imaging methods currently under development, which monitor ROS levels via 7 
oxidation/reduction of a probe compound, [18F]FSPG PET does not provide an index ROS 8 
production per se. Rather, it provides a measure of cellular antioxidant response (i.e. increased 9 
GSH biosynthesis). An advantage of this approach is that adaptive changes such as increased GSH 10 
biosynthesis represent processes down-stream of ROS and are therefore more proximal to desired 11 
outcomes such as cell death. Indeed, rather than killing cells directly, ROS induce intervening 12 
redox biochemical changes, including GSH depletion and alteration of thiol/disulfide balance, 13 
which in turn trigger apoptosis (43). While we have provided evidence that glutamate levels are 14 
unaltered during oxidative stress, it is possible that non-redox related changes in glutamate, such 15 
as those associated with glutamate utilization in anaplerosis and energy metabolism, could 16 
confound interpretation of [18F]FSPG PET data. Nevertheless, our results suggest that during drug-17 
induced oxidative stress changes in [18F]FSPG retention are selectively mediated by the alteration 18 
of intracellular cystine. Furthermore, [18F]FSPG PET currently represents the only non-invasive 19 
imaging method to have reached a stage of development appropriate for further translation to 20 
human redox imaging studies. 21 
 22 
 24 
Several therapeutic strategies, including chemotherapy, radiotherapy and targeted therapies act in-1 
part to disrupt tumor redox homeostasis (44-46). As a consequence, the emergence of resistance 2 
to these therapies is often accompanied by enhanced antioxidant production (13). Specifically, 3 
doxorubicin’s therapeutic mechanism of action involves both the direct and indirect induction of 4 
oxidative stress oxidative stress via redox cycling, production of superoxide and hydrogen 5 
peroxide, and DNA damage (47). Tumor-associated [18F]FSPG was sensitive to doxil-induced 6 
changes in tumor redox status which occurred soon after the initiation of treatment but prior to 7 
measurable changes in tumor volume (Fig. 5). In particular, Doxil caused a depletion of tumor 8 
GSH potentially as either the direct result of Doxil-induced oxidative stress or via formation and 9 
efflux of Doxil-GSH conjugate by the multidrug-resistance-associated proteins (MRPs) (48). GSH 10 
depletion by either mechanism could presumably affect intracellular cystine levels by influencing 11 
de novo GSH synthesis. Therefore, [18F]FSPG could facilitate a precision medicine approach in 12 
which drug response could be predicted in individual patients based on redox response 13 
measurements. Moreover, given that steady-state levels of GSH are known to correlate well with 14 
drug resistance, a dynamic marker of GSH biosynthetic flux may provide further insights into drug 15 
resistance mechanisms in vivo. 16 
 17 
In conclusion, this study demonstrates in preclinical models of cancer, that a PET radiotracer used 18 
in clinical investigations is sensitive to tumor redox status. Oxidative stress-induced changes in 19 
[18F]FSPG retention were mediated by alterations of intracellular cystine, the dimeric form of 20 
cysteine, that is central to cellular responses to oxidative challenge. [18F]FSPG therefore represents 21 
a potentially valuable PET imaging agent for investigation of redox status in human disease. In 22 
 25 
cancer imaging, [18F]FSPG may show particular value given the importance of redox mechanisms 1 
in tumorigenesis, treatment response and the development of drug resistance. 2 
 3 
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FIGURE LEGENDS 1 
 2 
Figure 1. [18F]FSPG accumulation is altered following manipulation of the intracellular 3 
redox environment. (A) Flow cytometric measurement of total reactive oxygen species (ROS) 4 
levels using CellROX Orange, following treatment with TBHP (200 μM, 1 h), NAC (5 mM, 2 h), 5 
or the combined treatment (BOTH). (i) Representative CellROX Orange fluorescence histograms. 6 
(ii) Fold-change in median CellROX Orange fluorescence intensity relative to untreated cells (UT). 7 
Scatter plot points represent data from independent experiments, each performed as a single 8 
measurement. (B) Intracellular ratio of oxidized (GSSG) to reduced GSH following treatment with 9 
TBHP, NAC or BOTH. Scatter plot points represent independent experiments performed in 10 
duplicate or triplicate. (C) Western blot showing changes in protein expression following treatment 11 
with TBHP, NAC or BOTH. KGA and GAC, splice variants of K-type mitochondrial glutaminase; 12 
Nrf2, Nuclear factor (erythroid-derived 2)-like 2; Casp-3, inactive form of caspase 3; ΔCasp-3, 13 
active (cleaved) form of Casp-3. (D) Flow cytometric data in (i) UT and (ii) TBHP-treated cells 14 
showing levels of cell death as detected with Annexin V-alexafluor 488 (λ Ex/Em = 488/535) and 15 
Sytox Red staining (λ Ex/Em = 633/658). Q1 = viable; Q2 = early apoptotic; Q3 = late 16 
apoptotic/necrotic. (E) Molecular structure of [18F]FSPG. (F and G) Intracellular retention of 17 
[18F]FSPG (F) and [18F]FDG (G) following treatment with TBHP, NAC or BOTH. Scatter plot 18 
points represent independent experiments performed in triplicate. Data are presented as mean ± 19 
SD. ††† p < 0.001, Bonferroni multiple comparison-corrected single sample t test (versus unity); 20 
**** p < 0.0001, ** p < 0.01, *** p < 0.001, Bonferroni multiple comparison-corrected t test. 21 
TBHP, tert-butyl hydroperoxide; NAC, N-acetylcysteine. 22 
 23 
 24 
Figure 2. Decreased [18F]FSPG accumulation is correlated with the degree of oxidative stress. 25 
(A) Intracellular fluorescence of the reactive oxygen species (ROS)-sensitive fluorophore 26 
CellROX Green following treatment with vehicle (dimethyl sulfoxide, DMSO) or the ROS-27 
inducing compounds diethyl maleate (DEM, 100 μM, 24 h), antimycin A (AMA, 110 μg/mL, 1 28 
h), rotenone (ROT, 50 μM, 1 h), auranofin (AUR, 50 μM, 1 h), butein (100 μM, 24 h). Scatter plot 29 
points represent data from independent experiments, each performed as a single measurement. (B) 30 
 30 
Intracellular retention of [18F]FSPG following the above treatments. Scatter plot points represent 1 
independent experiments, each performed as a single measurement. (C) Correlation between 2 
CellROX Green fluorescence and intracellular [18F]FSPG accumulation. Broken lines represent 3 
the 95% confidence interval of the best fit line. Data are presented as mean ± SD. * p < 0.05, ** p 4 
< 0.01, *** p < 0.001, single sample t test (versus unity). For scatter plots, an F test was used to 5 
determine whether the line of best fit was significantly different from zero. 6 
 7 
 8 
Figure 3. Changes in [18F]FSPG accumulation are associated with alteration of intracellular 9 
cystine concentration. (A) Model of mechanisms influencing [18F]FSPG retention. Intracellular 10 
[18F]FSPG accumulation (black arrows indicate influx and efflux) is mediated by system xc--11 
mediated exchange with glutamate and cystine. The concentration gradients (wedges) and 12 
physiologically-relevant exchange directions (arrows) of glutamate (green) and cystine (red) are 13 
indicated. In addition to the influence of concentration gradients, both cystine and glutamate can 14 
compete with [18F]FSPG for binding to xCT, thereby inhibiting [18F]FSPG transport. Sites of 15 
competition are schematically illustrated as green and red asterisks. o and i represent extracellular 16 
and intracellular compartments, respectively. (B and C) Intracellular (B) and extracellular (C) 17 
levels of glutamate (Glu) following treatment with TBHP, NAC, or the combined treatment 18 
(BOTH). Data are presented as mean ± SD. Scatter plot points represent independent experiments 19 
performed in duplicate or triplicate. (D and E) Intracellular (D) and extracellular (E) levels of 20 
cystine following treatment with TBHP, NAC, or BOTH. Data are presented as mean ± SD. Scatter 21 
plot points represent replicate wells.  22 
 23 
 24 
Figure 4. Oxidative stress decreases intracellular cystine via stimulation of GSH 25 
biosynthesis. (A) Cells were fed with [U-13C6, U-15N2]cystine (200 µM) and the fate of the isotopic 26 
label within the GSH biosynthetic pathway was followed in cell lysates using LC-MS. Red dots 27 
indicate the position of carbon-13/nitogen-15 label. (B-F) Intracellular levels of labelled 28 
metabolites in lysates from untreated cells and cells treated with TBHP (200 μM, 1 h). (B) cystine 29 
[(Cys)2, M+8 molecular species]; (C) cysteine (Cys, M+4); (D) γ-glutamylcysteine (γ-GC, M+4); 30 
(E) reduced GSH (M+4); and (F) oxidized GSH (GSSG, M+4). Data are presented as mean ± SD 31 
 31 
of three replicate wells. Trx, thioredoxin; TrxR1, thioredoxin reductase 1; GCL, glutamate-1 
cysteine ligase; GS, glutathione synthetase; Gly, glycine. o and i represent extracellular and 2 
intracellular compartments, respectively. 3 
 4 
 5 
Figure 5. Treatment with the chemotherapeutic Doxil causes changes in tumor redox status 6 
that precede tumor shrinkage. (A) Doxil treatment regime. Mice received s.c. inoculation of 7 
A2780 ovarian cancer cells. Day 0 (D0) was defined for each mouse as the day at which its tumor 8 
reached 100 mm3 (10-12 d growth). Mice were then assigned to either the untreated, 24 h (D1) or 9 
6 day (D6) treatment groups. The untreated group was imaged on D0. The 24 h treatment group 10 
received Doxil treatment (10 mg/kg, i.p.) on D0 and was imaged on D1, and to the 6 day treatment 11 
group received Doxil treatment on D0, D2 and D5 and was imaged on D6. (B) Tumor growth 12 
curves in untreated mice (D0) and mice treated with Doxil for 24 h (D1) or 6 days (D6). Data 13 
represent mean ± SD (n = 4-5 mice). (C and D) Total GSH (C) levels and the ratio of GSSG to 14 
GSH (D) in tumors excised after imaging. Scatter plot points represent measurements from 15 
individual animals performed in duplicate or triplicate. (E) Representative [18F]FSPG PET volume 16 
rendered technique PET/CT images from mice receiving no Doxil (D0), 24 h (D1) or 6 days of 17 
Doxil treatment (D6). Tumors are indicated by white arrows. (F) Quantified [18F]FSPG tumor 18 
retention in mice treated as above.  * p < 0.05, ** p < 0.01, *** p < 0.001, p < 0.0001, Bonferroni 19 
multiple comparison-corrected t test versus D0 group. 20 





